PE20060016A1 - Solidos supersaturados estabilizados de drogas lipofilicas - Google Patents
Solidos supersaturados estabilizados de drogas lipofilicasInfo
- Publication number
- PE20060016A1 PE20060016A1 PE2005000277A PE2005000277A PE20060016A1 PE 20060016 A1 PE20060016 A1 PE 20060016A1 PE 2005000277 A PE2005000277 A PE 2005000277A PE 2005000277 A PE2005000277 A PE 2005000277A PE 20060016 A1 PE20060016 A1 PE 20060016A1
- Authority
- PE
- Peru
- Prior art keywords
- solvent
- refers
- amorphous silica
- lipophilic drugs
- steroid molecule
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 239000002904 solvent Substances 0.000 abstract 4
- 150000003431 steroids Chemical class 0.000 abstract 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-HQMMCQRPSA-N Ethanol-14C Chemical compound C[14CH2]O LFQSCWFLJHTTHZ-HQMMCQRPSA-N 0.000 abstract 1
- -1 HORMONES OR STEROIDS Chemical class 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960004766 estradiol valerate Drugs 0.000 abstract 1
- 230000008020 evaporation Effects 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 150000002634 lipophilic molecules Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract 1
- 239000008158 vegetable oil Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04075714 | 2004-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060016A1 true PE20060016A1 (es) | 2006-02-16 |
Family
ID=34928105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000277A PE20060016A1 (es) | 2004-03-10 | 2005-03-10 | Solidos supersaturados estabilizados de drogas lipofilicas |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8715735B2 (https=) |
| EP (2) | EP2087883B1 (https=) |
| JP (1) | JP5006185B2 (https=) |
| KR (1) | KR101210695B1 (https=) |
| CN (1) | CN1984644B (https=) |
| AR (1) | AR048500A1 (https=) |
| AT (1) | ATE442131T1 (https=) |
| AU (1) | AU2005221403B8 (https=) |
| BR (1) | BRPI0507342A (https=) |
| CA (1) | CA2558582C (https=) |
| CR (1) | CR8630A (https=) |
| DE (1) | DE602005016551D1 (https=) |
| DK (1) | DK1765290T3 (https=) |
| EA (1) | EA012746B1 (https=) |
| EC (1) | ECSP066902A (https=) |
| ES (2) | ES2390406T3 (https=) |
| GT (1) | GT200500045A (https=) |
| HR (1) | HRP20090614T1 (https=) |
| IL (1) | IL177894A0 (https=) |
| MY (1) | MY142989A (https=) |
| NO (1) | NO20064473L (https=) |
| NZ (1) | NZ549793A (https=) |
| PA (1) | PA8626101A1 (https=) |
| PE (1) | PE20060016A1 (https=) |
| PL (1) | PL1765290T3 (https=) |
| PT (1) | PT1765290E (https=) |
| RS (1) | RS51076B (https=) |
| SI (1) | SI1765290T1 (https=) |
| SV (1) | SV2005002044A (https=) |
| TW (1) | TWI345986B (https=) |
| UY (1) | UY28803A1 (https=) |
| WO (1) | WO2005087199A2 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10172810B2 (en) | 2003-02-24 | 2019-01-08 | Pharmaceutical Productions, Inc. | Transmucosal ketamine delivery composition |
| EP1904028A1 (en) * | 2005-06-16 | 2008-04-02 | Warner Chilcott Company Inc. | Estrogen compositions for vaginal administration |
| CN101232869B (zh) * | 2005-06-16 | 2016-03-02 | 沃纳奇尔科特有限责任公司 | 局部给药的凝胶组合物 |
| JP2009536165A (ja) * | 2006-05-10 | 2009-10-08 | エボニック デグサ ゲーエムベーハー | 医薬組成物におけるロール圧縮された熱分解的に製造された二酸化ケイ素の使用 |
| MX2009008935A (es) | 2007-02-23 | 2009-11-02 | Gilead Sciences Inc | Moduladores de las propiedades farmacocineticas de productos terapeuticos. |
| ES2575549T3 (es) * | 2007-04-11 | 2016-06-29 | John A. Mccarty | Comprimido de melatonina y métodos de preparación y uso |
| BRPI0908477A2 (pt) * | 2008-02-13 | 2018-03-27 | Bayer Schering Pharma Ag | sistema de distribuição de medicamento contendo estradiol |
| CN102083467B (zh) | 2008-03-11 | 2013-12-25 | Aska制药株式会社 | 固体分散体及其药物组合物、以及它们的制备方法 |
| MX2010011963A (es) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| WO2009138224A1 (en) * | 2008-05-14 | 2009-11-19 | Helm Ag | Pharmaceutical composition comprising drospirenone |
| JP2012505253A (ja) * | 2008-10-10 | 2012-03-01 | テバ ウィメンズ ヘルス インコーポレイテッド | 低用量酢酸シプロテロンを用いる、去勢された前立腺癌患者における血管運動症状の治療方法 |
| WO2010094623A1 (en) * | 2009-02-18 | 2010-08-26 | Bayer Schering Pharma Aktiengesellschaft | Formulation comprising drospirenone for subcutaneous or intramuscular administration |
| WO2010111397A1 (en) * | 2009-03-24 | 2010-09-30 | Adds Pharmaceuticals Llc | Stabilized solubility-enhanced formulations for oral delivery |
| FR2947178B1 (fr) * | 2009-06-29 | 2012-07-06 | Effik | Composition pharmaceutique a base de progesterone micronisee et ses utilisations |
| AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
| US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
| US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
| WO2012120365A1 (en) | 2011-03-07 | 2012-09-13 | Aurobindo Pharma Limited | Stable pharmaceutical composition comprising ethinyl estradiol |
| US20140178479A1 (en) * | 2011-08-12 | 2014-06-26 | Perosphere, Inc. | Concentrated Felbamate Formulations for Parenteral Administration |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CN113842362A (zh) | 2012-11-14 | 2021-12-28 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20140303128A1 (en) * | 2013-03-14 | 2014-10-09 | Pharmaceutical Productions Inc. | Transmucosal hormone delivery system |
| EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| ES2995732T3 (en) | 2014-07-21 | 2025-02-11 | Pharmaceutical Productions Inc | Solid dosage form composition for buccal or sublingual administration of cannabinoids |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| CN106109420B (zh) * | 2016-08-11 | 2018-07-06 | 吴启旸 | 依普利酮固体分散体及其制剂 |
| AU2018222468B2 (en) * | 2017-02-14 | 2023-05-11 | Dsm Ip Assets B.V. | Water dispersible formulations |
| KR102605784B1 (ko) * | 2017-02-14 | 2023-11-24 | 디에스엠 아이피 어셋츠 비.브이. | 저장-안정성 제형 |
| CN110013467B (zh) * | 2018-01-10 | 2021-09-17 | 上海汉都医药科技有限公司 | 一种固体微粒及其制备方法和含其的药物组合物 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
| JP7847966B2 (ja) * | 2020-10-23 | 2026-04-20 | 富士製薬工業株式会社 | 医薬製剤およびその製造方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA72698B (en) * | 1972-02-03 | 1973-09-26 | Liebenberg R W | Method of preparing medicinal compositions |
| US4013785A (en) | 1975-03-21 | 1977-03-22 | Bristol-Myers Company | Apap tablet containing fumed silica and process for manufacturing same |
| DE2845326C2 (de) * | 1978-10-18 | 1985-05-23 | Beiersdorf Ag, 2000 Hamburg | Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung |
| GB8403359D0 (en) | 1984-02-08 | 1984-03-14 | Erba Farmitalia | Pharmaceutical compositions |
| IT1216570B (it) * | 1988-04-08 | 1990-03-08 | Vectorpharma Int | Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione. |
| DE3916112A1 (de) | 1989-05-16 | 1990-11-22 | Schering Ag | Dihydrospirorenon als antiandrogen |
| DE69101291T2 (de) | 1990-08-30 | 1994-07-07 | Senju Pharma Co | Zusammensetzung zur kontrollierten Abgabe von Medikamenten. |
| DE69016788T2 (de) * | 1990-11-29 | 1995-06-22 | Faulding F H & Co Ltd | Verfahren zur Herstellung von Flüssigkeiten enthaltenden Pulvern. |
| DE4326240A1 (de) | 1993-08-02 | 1995-02-09 | Schering Ag | 15,15-Dialkyl-substituierte Derivate des Estradiols |
| US5585115A (en) * | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| US5789442A (en) | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
| US5800834A (en) | 1996-06-10 | 1998-09-01 | Spireas; Spiridon | Liquisolid systems and methods of preparing same |
| US6027747A (en) | 1997-11-11 | 2000-02-22 | Terracol; Didier | Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions |
| KR20000000016A (ko) | 1999-02-10 | 2000-01-15 | 김일 | 자동차용번호판부착볼트구조 |
| JP4354667B2 (ja) * | 1999-08-31 | 2009-10-28 | バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト | 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| KR100913910B1 (ko) | 2000-01-18 | 2009-08-26 | 바이엘 쉐링 파마 악티엔게젤샤프트 | 호르몬 보충 요법용 드로스피렌온 |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| OA12625A (en) * | 2001-06-22 | 2006-06-12 | Pfizer Prod Inc | Pharmaceutical compositions of adsorbates of amorphous drug. |
| ITMC20010031U1 (it) | 2001-07-05 | 2003-01-07 | Best Raffaello Srl | Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo |
| SE0103838D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Pharmaceutical formulation & product |
| US7943602B2 (en) | 2002-09-05 | 2011-05-17 | Pantarhei Bioscience B.V. | Pharmaceutical application of 15- or 16-substituted testosterone analogues |
| DE60330888D1 (de) | 2002-11-05 | 2010-02-25 | Bayer Schering Pharma Ag | Verwendung von drospirenon zur behandlung von hypertension |
| DE20217332U1 (de) | 2002-11-11 | 2003-02-27 | Brand Factory Swiss Gmbh, Rotkreuz | Socke |
| EP1601347A1 (en) * | 2003-02-19 | 2005-12-07 | LifeCycle Pharma A/S | Use of a silica or silica derivative as a sorption material |
| FR2851918B1 (fr) | 2003-03-06 | 2006-06-16 | Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication | |
| ATE429900T1 (de) | 2004-03-10 | 2009-05-15 | Bayer Schering Pharma Ag | Zusammensetzungen aus drospirenon in molekularer dispersion |
-
2005
- 2005-03-09 MY MYPI20050963A patent/MY142989A/en unknown
- 2005-03-10 DE DE602005016551T patent/DE602005016551D1/de not_active Expired - Lifetime
- 2005-03-10 HR HR20090614T patent/HRP20090614T1/hr unknown
- 2005-03-10 BR BRPI0507342-1A patent/BRPI0507342A/pt not_active IP Right Cessation
- 2005-03-10 AU AU2005221403A patent/AU2005221403B8/en not_active Ceased
- 2005-03-10 CN CN2005800150633A patent/CN1984644B/zh not_active Expired - Fee Related
- 2005-03-10 EP EP09161378A patent/EP2087883B1/en not_active Expired - Lifetime
- 2005-03-10 PA PA20058626101A patent/PA8626101A1/es unknown
- 2005-03-10 AR ARP050100924A patent/AR048500A1/es not_active Application Discontinuation
- 2005-03-10 UY UY28803A patent/UY28803A1/es not_active Application Discontinuation
- 2005-03-10 ES ES09161378T patent/ES2390406T3/es not_active Expired - Lifetime
- 2005-03-10 PT PT05718248T patent/PT1765290E/pt unknown
- 2005-03-10 PL PL05718248T patent/PL1765290T3/pl unknown
- 2005-03-10 ES ES05718248T patent/ES2332229T3/es not_active Expired - Lifetime
- 2005-03-10 WO PCT/IB2005/000748 patent/WO2005087199A2/en not_active Ceased
- 2005-03-10 US US11/076,022 patent/US8715735B2/en not_active Expired - Fee Related
- 2005-03-10 SV SV2005002044A patent/SV2005002044A/es unknown
- 2005-03-10 SI SI200530840T patent/SI1765290T1/sl unknown
- 2005-03-10 JP JP2007502437A patent/JP5006185B2/ja not_active Expired - Fee Related
- 2005-03-10 GT GT200500045A patent/GT200500045A/es unknown
- 2005-03-10 TW TW094107345A patent/TWI345986B/zh not_active IP Right Cessation
- 2005-03-10 DK DK05718248T patent/DK1765290T3/da active
- 2005-03-10 CA CA2558582A patent/CA2558582C/en not_active Expired - Fee Related
- 2005-03-10 AT AT05718248T patent/ATE442131T1/de active
- 2005-03-10 PE PE2005000277A patent/PE20060016A1/es not_active Application Discontinuation
- 2005-03-10 NZ NZ549793A patent/NZ549793A/en unknown
- 2005-03-10 RS RSP-2009/0508A patent/RS51076B/sr unknown
- 2005-03-10 EP EP05718248A patent/EP1765290B1/en not_active Expired - Lifetime
- 2005-03-10 EA EA200601588A patent/EA012746B1/ru not_active IP Right Cessation
-
2006
- 2006-09-05 IL IL177894A patent/IL177894A0/en unknown
- 2006-09-14 CR CR8630A patent/CR8630A/es unknown
- 2006-10-02 NO NO20064473A patent/NO20064473L/no not_active Application Discontinuation
- 2006-10-02 EC EC2006006902A patent/ECSP066902A/es unknown
- 2006-10-09 KR KR1020067020937A patent/KR101210695B1/ko not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20060016A1 (es) | Solidos supersaturados estabilizados de drogas lipofilicas | |
| Tang et al. | Self-emulsifying drug delivery systems: strategy for improving oral delivery of poorly soluble drugs | |
| AU2020416292B2 (en) | Oral dissolvable film and method of manufacturing and using the same | |
| CA2716874A1 (en) | A pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases | |
| AR114051A2 (es) | Composiciones farmacéuticas y supositorio vaginal | |
| Zhao et al. | Anti-nociceptive and anti-inflammatory effects of Croton crassifolius ethanol extract | |
| BR9814729A (pt) | Método e composição de uma preparação oral de itraconazol | |
| AR054328A1 (es) | Formas farmaceuticas resistentes a la rotura con liberacion sostenida | |
| RU2010128471A (ru) | Фармацевтические композиции для чрескожного введения, содержащие стероидный гормон | |
| WO2008120711A1 (ja) | タミバロテンカプセル剤 | |
| ES2323082T5 (es) | Agente formador de oleogeles, que contiene triterpenos, un oleogel que contiene triterpenos y procedimiento para la producción de un oleogel que contiene triterpenos. | |
| PE20070377A1 (es) | Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol | |
| CL2007003590A1 (es) | Compuestos derivados de aril sulfamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en prevencion y tratamiento de sintomas vasomotrices, disfuncion sexual, transtornos gastrointestinales, transt | |
| PE20090878A1 (es) | Composicion orodispersable sin mal olor o mal sabor que comprende acidos grasos poliinsaturados | |
| RU2015139983A (ru) | СОСТАВ С АМОРФНЫМ L-5-МЕТИЛТЕТРАГИДРОФОЛАТОМ КАЛЬЦИЯ (L-5-MTГФ-Cа) | |
| WO2005079751A3 (en) | Oral pharmaceutical compositions of candesartan cilexetil | |
| RU2003126135A (ru) | Композиция биологически активных веществ | |
| WO2016030705A1 (en) | Plant extracts and related compositions, methods and systems | |
| Rojas-Bedolla et al. | Chemical characterization, pharmacological effects, and toxicity of an ethanol extract of Celtis pallida Torr.(Cannabaceae) aerial parts | |
| US9422701B2 (en) | Toilet water splash inhibiting device | |
| Liu et al. | Transdermal anti-inflammatory effects and mechanisms of hydrogel patches containing seco-iridoids from Gentiana macrophylla Pall | |
| PE20081491A1 (es) | Composicion farmaceutica que comprende (r)-5,6-dimetoxi-2-[2,2,4,6,7-pentametil-3-(4-metilfenil)-2,3-dihidro-1-benzofuran-5-il)isoindolina y un componente lipofilico | |
| IT202000030914A1 (it) | Composizione farmaceutica solida di ademetionina e cannabidiolo e procedimento per ottenerla | |
| ES2688119T3 (es) | Formulación farmacéutica para el tratamiento de cambios inflamatorios del recto | |
| Le et al. | Microcrystalline cellulose from coir pith as a pH-triggered and mucoadhesive carrier for curcumin delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |